Cutting edge: Antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction.
about
Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overviewSystemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.Activation of cGAS-dependent antiviral responses by DNA intercalating agents.Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Immunomodulators in SLE: Clinical evidence and immunologic actions.Why targeted therapies are necessary for systemic lupus erythematosus.cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling.Absent in Melanoma 2 proteins in SLE.Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?An RNA-Based Fluorescent Biosensor for High-Throughput Analysis of the cGAS-cGAMP-STING Pathway.A 44-year-old man with eye, kidney, and brain dysfunction.Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice.Cyclic GMP-AMP Synthase Is Required for Cell Proliferation and Inflammatory Responses in Rheumatoid Arthritis Synoviocytes.Trafficking-Mediated STING Degradation Requires Sorting to Acidified Endolysosomes and Can Be Targeted to Enhance Anti-tumor Response.Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?Expression of Cyclic GMP-AMP Synthase in Patients With Systemic Lupus Erythematosus.Human plasmacytoid dentritic cells elicit a Type I Interferon response by sensing DNA via the cGAS-STING signaling pathway.
P2860
Q37415269-B4678523-710F-4E28-A867-BDFFB7973BE5Q38534457-79886974-AF55-4D10-8E88-E1B5E4A2F757Q38742855-27F41640-9B0A-41D4-ACA8-0B7DCDE8A8C8Q38850089-0DF2DE80-552E-4CF3-B9B6-4108D1A4A439Q38883883-7531B904-3D8B-4F86-96D5-B4F025492C7AQ38920435-F9E918C9-1855-4A6F-879A-9000B9AAD0F3Q38972881-0EFD208F-974D-491D-A6D5-8885619EBE51Q39071091-42FE84F9-BC92-4C87-87FB-096239F2E2D6Q39517523-F1A83FDD-1A21-4631-B4E9-9137A3ACBFBCQ40434927-2DFC282B-24B4-468B-BFF0-041C8853D53BQ41070317-3F1BF4A4-B16C-48F0-833D-249C82B94AC7Q42367804-BDAA994C-D341-4B52-82C1-06969367CFD3Q43097764-F090303D-D30E-4501-A9C6-12C72942969FQ47293147-64CE2826-B4C6-4E87-9D4D-96196A046D00Q47900605-6B43C8B0-8BAB-4E46-AE25-8B985D984790Q51317974-9A87DB62-D914-490C-9655-C26D02403177Q54197779-0274E36A-63F5-476F-8A0B-FF79A4EFE8D2
P2860
Cutting edge: Antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@ast
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@en
type
label
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@ast
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@en
prefLabel
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@ast
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@en
P2093
P2860
P356
P1476
Cutting edge: Antimalarial dru ...... -AMP synthase-DNA interaction.
@en
P2093
Joshua J Woodward
Keith B Elkon
Mark Minie
Tomikazu Sasaki
P2860
P304
P356
10.4049/JIMMUNOL.1402793
P407
P577
2015-03-27T00:00:00Z